Complex Relationships between Diagnostics and Survival in Chronic Lymphocytic Leukemia in Denmark, Finland, Norway, and Sweden
Open Access
Abstract
Background: Chronic lymphocytic leukemia (CLL) is a common hematological malignancy with highly variable clinical presentation. Many patients never require any treatment but for the others, chemotherapy, immunochemotherapy, and newer targeted therapies have changed the treatment landscape. Diagnostic age influences the applied treatment, and we thus wanted to analyze age-specific survival trends through 50 years up to 2020s. Methods: We used 1- and 5-year relative survival from the NORDCAN database, with data from Denmark (DK), Finland (FI), Norway (NO), and Sweden (SE). Because of the variable presentation of CLL, we also considered incidence and mortality trends. For comparison, US SEER data were used. Results: The large age-specific survival differences in 1972–76 almost disappeared by 2017–21. While 5-year survival in younger patients exceeded 90%, for those diagnosed at age 80–89 years, survival reached 90% in DK and SE women, 80% in NO and SE men, but only 50% in FI. DK 5-year overall survival for men was 92.4%, and for women, it was 96.3%. These survival figures were higher than age-group-specific US survival data. Conclusions: The DK data are probably global top figures for national survival which could be achieved by boosting survival even among the oldest patients. The qualification to these figures and international comparisons is that survival needs to be considered in terms of incidence, which is high in DK and NO. Low survival of the FI 80–89-year-old patients, even in the first year after diagnosis, may suggest delayed diagnosis, which should call for a closer national scrutiny.Keywords
Funding Information
- National Institute for Cancer Research—NICR (LX22NPO5102, CZ.02.01.01/00/22_008/0004644)
- European Union-Next Generation EU (LX22NPO5102, CZ.02.01.01/00/22_008/0004644)
- Jane and Aatos Erkko Foundation, Sigrid Juselius Foundation, Finnish Cancer Organizations, University of Helsinki, Helsinki University Central Hospital, Novo Nordisk Foundation, Päivikki and Sakari Sohlberg Foundation (LX22NPO5102, CZ.02.01.01/00/22_008/0004644)
This publication has 47 references indexed in Scilit:
- Mortality in patients with lymphoid malignancies and multiple myeloma was stable upon and during the COVID‐19 pandemic: A population‐based, nation‐wide studyHemaSphere, 2024
- Lymphoid blood cancers, incidence and survival 2005-2023: A report from the UK’s Haematological Malignancy Research NetworkCancer Epidemiology, 2023
- Characterization of real‐world treatment practices and outcomes among patients with chronic lymphocytic leukemia treated in a Finnish tertiary centereJHaem, 2021
- Survival trends in chronic lymphocytic leukemia across treatment eras: US SEER database analysis (1985–2017)Annals of Hematology, 2021
- Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnnals of Oncology, 2021
- National trends in incidence and survival of chronic lymphocytic leukemia in Norway for 1953–2012: a systematic analysis of population‐based dataCancer Medicine, 2016
- Survival variations by country and age for lymphoid and myeloid malignancies in Europe 2000–2007: Results of EUROCARE-5 population-based studyEuropean Journal of Cancer, 2015
- Cancer patient pathways in Denmark as a joint effort between bureaucrats, health professionals and politicians—A national Danish projectHealth Policy, 2012
- Comparability of cancer identification among Death Registry, Cancer Registry and Hospital Discharge RegistryInternational Journal of Cancer, 2012
- An alternative approach to age adjustment of cancer survival ratesEuropean Journal of Cancer, 2004